The impact of race, ethnicity, age and sex on clinical outcome in chronic lymphocytic leukemia: a comprehensive Surveillance, Epidemiology, and End Results analysis in the modern era

References

• Blackstock AW, Herndon JE 2nd, Paskett ED, et al. Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. J Natl Cancer Inst 2002;94:284–290.
   PubMed Web of Science ®Google Scholar
• Godley PA, Schenck AP, Amamoo MA, et al. Racial differences in mortality among Medicare recipients after treatment for localized prostate cancer. J Natl Cancer Inst 2003;95:1702–1710.
   PubMed Web of Science ®Google Scholar
• Hershman DL, Unger JM, Barlow WE, et al. Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897. J Clin Oncol 2009;27:2157–2162.
   PubMed Web of Science ®Google Scholar
• Albain KS, Unger JM, Crowley JJ, et al. Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. J Natl Cancer Inst 2009;101:984–992.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Byrtek M, Taylor MD, et al. Racial differences in presentation and management of follicular non-Hodgkin lymphoma in the United States: report from the National LymphoCare Study. Cancer 2012;118:4842–4850.
   PubMed Web of Science ®Google Scholar
• Siegel R, Desantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012;62:220–241.
   PubMed Web of Science ®Google Scholar
• Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004;103:1202–1210.
   PubMed Web of Science ®Google Scholar
• Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 2010;376:1164–1174.
   PubMed Web of Science ®Google Scholar
• Kay NE, Geyer SM, Call TG, et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007;109:405–411.
   PubMed Web of Science ®Google Scholar
• Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 2010;116:e90–e98.
   PubMed Web of Science ®Google Scholar
• Robak T, Dmoszynska A, Solal-Celigny P, et al. Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia. J Clin Oncol 2010;28:1756–1765.
   PubMed Web of Science ®Google Scholar
• Krieger N. Socioeconomic data in cancer registries. Am J Public Health 2001;91:156–157.
   PubMed Web of Science ®Google Scholar
• Brown CC. The statistical comparison of relative survival rates. Biometrics 1983;39:941–948.
   PubMed Web of Science ®Google Scholar
• Hillmen P, Skotnicki AB, Robak T, et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007;25:5616–5623.
   PubMed Web of Science ®Google Scholar
• Knauf WU, Lissichkov T, Aldaoud A, et al. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 2009;27:4378–4384.
   PubMed Web of Science ®Google Scholar
• Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749–1755.
   PubMed Web of Science ®Google Scholar
• Matasar MJ, Ritchie EK, Consedine N, et al. Incidence rates of the major leukemia subtypes among US Hispanics, Blacks, and non-Hispanic Whites. Leuk Lymphoma 2006;47:2365–2370.
   PubMed Web of Science ®Google Scholar
• Chevannes M. Access to health care for black people. Health Visit 1991;64:16–17.
   PubMedGoogle Scholar
• Cornelius LJ. Access to medical care for black Americans with an episode of illness. J Natl Med Assoc 1991;83:617–626.
   PubMed Web of Science ®Google Scholar
• Ginzberg E. Access to health care for Hispanics. JAMA 1991; 265:238–241.
   PubMed Web of Science ®Google Scholar
• Shenoy PJ, Malik N, Sinha R, et al. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States. Clin Lymphoma Myeloma Leuk 2011;11:498–506.
   PubMed Web of Science ®Google Scholar
• Coombs CC, Falchi L, Weinberg JB, et al. Chronic lymphocytic leukemia in African Americans. Leuk Lymphoma 2012;53: 2326–2329.
   PubMed Web of Science ®Google Scholar
• Costa LJ, Xavier AC, Wahlquist AE, et al. Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood 2013;121:4861–4866.
   PubMed Web of Science ®Google Scholar
• Nabhan C, Aschebrook-Kilfoy B, Chiu B, et al. The impact of race, age, and sex in follicular lymphoma (FL): a comprehensive SEER analysis in the pre- and post-rituximab eras. Blood 2012;120(Suppl. 1): Abstract 1576.
   Google Scholar
• Sarfati D, Blakely T, Pearce N. Measuring cancer survival in populations: relative survival vs cancer-specific survival. Int J Epidemiol 2010;39:598–610.
   PubMed Web of Science ®Google Scholar
• Seftel MD, Demers AA, Banerji V, et al. High incidence of chronic lymphocytic leukemia (CLL) diagnosed by immunophenotyping: a population-based Canadian cohort. Leuk Res 2009;33:1463–1468.
   PubMed Web of Science ®Google Scholar
• Keegan TH, McClure LA, Foran JM, et al. Improvements in survival after follicular lymphoma by race/ethnicity and socioeconomic status: a population-based study. J Clin Oncol 2009;27:3044–3051.
   PubMed Web of Science ®Google Scholar
• Halpern MT, Ward EM, Pavluck AL, et al. Association of insurance status and ethnicity with cancer stage at diagnosis for 12 cancer sites: a retrospective analysis. Lancet Oncol 2008;9:222–231.
   PubMed Web of Science ®Google Scholar
• Ward E, Halpern M, Schrag N, et al. Association of insurance with cancer care utilization and outcomes. CA Cancer J Clin 2008;58:9–31.
   PubMed Web of Science ®Google Scholar
• Clarke CA, Glaser SL, Gomez SL, et al. Lymphoid malignancies in U.S. Asians: incidence rate differences by birthplace and acculturation. Cancer Epidemiol Biomarkers Prev 2011;20:1064–1077.
   PubMed Web of Science ®Google Scholar
• Wu SJ, Huang SY, Lin CT, et al. The incidence of chronic lymphocytic leukemia in Taiwan, 1986–2005: a distinct increasing trend with birth-cohort effect. Blood 2010;116:4430–4435.
   PubMed Web of Science ®Google Scholar